Table 2:
Literature review of secondary MDS/AML associated with certain chemotherapy agents.
| Chemotherapy | Primary Malignancy | Age | MDS/AML | Karyotyping | Time to MDS/AML (months) |
|---|---|---|---|---|---|
| Anti-metabolites (5FU/capecitabine) | Colon cancer [20] | 60 | AML | t(3;21)(q26;q22) | 39 |
| Gastric cancer [21] | 49 | AML | NA | 36 | |
| Colon cancer [22] | 68 | AML | Monosomy 7 | 30 | |
| Colon cancer [23] | 74 | AML | 46,XY, inv(3)(q21q26.2), del(5)(q13q33), add(7)(q11.2), add(11)(q23), add(15)(p13), and del(16)(q11.1) | 9 | |
| Oxaliplatin | Colon, cancer [24] | 56 | AML | 46;XX,−3,add(5)(q13),add(7)(q32)/46, idem+8/45, idem,add(20)(q13.3)/44–46, idem,−11,+0–2mar,+1–2r/45, idem, del(21)(q22) | 30 |
| Rectal cancer [25] | 71 | MDS | Monosomy 7 | 36 | |
| Colorectal cancer [26 ] | 74 | AML | inv(3)(q21q26.2), del(5)(q13q33), add(7)(q11.2), add(11)(q23), add(15)(p13), del(16)(q11.1) del 7q t(15;17)(q22;q21) | 9 | |
| Gastric cancer [26] | 68 | APML | 46,XY,t(15;17)(q22;q21)(15)/46,idem, −9,+add(9)(p22)(2)/46,XY(3) | 44 | |
| Colon [27] | 65 | APML | 45,XX,der(6)t(6;17)(p25;q22),−13,der(14)t(14;16)(p11;p11),−16,der(17)(dupq12q21),i(21)(q10),+i(21)(q10) | ~60 | |
| Taxanes (Paclitaxel, docetaxel, nab-paclitaxel) | Ovarian cancer (2 cases) [28] | 57 & 53 | AML | inv(16)(p13q22) inv(16)(p13q22) |
22 & 17 |
| Ovarian cancer [29] | 73 | MDS/AML | 46, XX, der(5;9)(p10:q10),del(7)(q?), +19, add (3) (q21), der(12), add (12) (p13)t(3:12)(q21:q22), del(12)(p?) | 22 | |
| Ovarian cancer [30] | 66 | MDS/MPN | De15q31 and 7q31 | 27 | |
| Endometrial cancer [31] | 63 | MDS/AML | 45,XX,add(3)(p13), del(3)(q23q25),−5,add(5)(q 13),add(7)(q11.2), der(17)t(5,17)(q15;q25) | 12 | |
| Ovarian cancer [32] | 75 | MDS | 45 XX t(1,5) (q25;q35), del (4) (q21q26), ins (7) (p15;?), del(12)(p12), −13, −17, −17, add(19)(p13.3), add(22)(q13),+2mar in 11 metaphases and 43–45,XX, t(1;5)(q25;q35),del(4)(q21q26), ins(7)(p15;?) del(12)(p12), −13, −17, −17, add (19) (p13.3), add (22)(q13), +2–4mar | 1.06 | |
| Ovarian cancer [33] | 52 | AML | NA | ~30 | |
| Breast [34] | 62 | AML | NA | 44 | |
| Cisplatin | Esophageal cancer (two cases) [35] | −48 −51 | AML | −(46,X,-Y, add(3)(q29), del(5)(q13q31), −6, +15,+16). −45 X,-Y, t(8;21) | −55 −20 |
| Laryngeal cancer [16] | 64 | AML | 41–45,XY,−1,−5,+mar/52,XY, +6 mar | ~36 | |
| Esophageal cancer [36 ] | 70 | AML | 46XY | 32 |